首页> Critical reviews in oncology/hematology> Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials.

Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials.

导出 LinkOut

翻译打印收藏纠错

第一作者： B,El Osta

第一单位： Department of Hematology/Medical Oncology, Atlanta VA Medical Center, Decatur, GA 30033, United States; Winship Cancer Institute of Emory University, Atlanta, GA 30322, United States.

作者： B,El Osta ^[1] ; F,Hu ^[2] ; R,Sadek ^[2] ; R,Chintalapally ^[3] ; S-C,Tang ^[4]

作者单位： Department of Hematology/Medical Oncology, Atlanta VA Medical Center, Decatur, GA 30033, United States; Winship Cancer Institute of Emory University, Atlanta, GA 30322, United States. ^[1] Georgia Cancer Center, Medical College of Georgia at Augusta University, Augusta, GA 30912, United States. ^[2] Department of Hematology/Oncology, Georgia Cancer Center, Medical College of Georgia at Augusta University, Augusta, GA 30912, United States. ^[3] Department of Hematology/Oncology, Georgia Cancer Center, Medical College of Georgia at Augusta University, Augusta, GA 30912, United States; Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. Electronic address: stang@augusta.edu. ^[4]

关键词 Checkpoint inhibitors Clinical trials Immune-related adverse events Meta-analysis Systematic review

医学主题词抗体, 单克隆(Antibodies, Monoclonal);人类(Humans);肿瘤(Neoplasms)

DOI 10.1016/j.critrevonc.2017.09.002

PMID 29065979

发布时间 2022-04-10

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交